Welcome to our dedicated page for AbCellera Biologics SEC filings (Ticker: ABCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbCellera Biologics Inc. filings document regulatory disclosures for a clinical-stage biotechnology company developing antibody-based medicines. Form 8-K reports cover financial and operational results, Regulation FD presentations, ABCL635 clinical program updates, patent settlement and license matters, and leadership or board changes.
Proxy materials describe governance matters, board composition, committee service, director independence, executive compensation, equity awards, and shareholder voting items. The filing record also reflects the company’s status as a British Columbia registrant with securities listed on Nasdaq under the symbol ABCL.
AbCellera Biologics is a clinical-stage biotechnology company focused on antibody medicines. For the quarter ended June 30, 2026, it generated $4.1 million in revenue and recorded a net loss of $55.4 million, or $0.18 per share, reflecting sharply lower licensing and royalty revenue and higher research and development spending.
Despite ongoing losses, liquidity remains strong with $540.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, and operating cash outflow improved to $7.6 million for the first half of 2026. The company also has access to an estimated $110.0 million of future government funding.
Strategically, AbCellera signed a major collaboration with Jazz Pharmaceuticals, receiving a $56.0 million non-refundable upfront payment and eligibility for substantial milestones and royalties on T‑cell engaging antibodies. A separate agreement with Vertex Pharmaceuticals added $28.0 million upfront and additional potential milestone and royalty streams, while internal programs ABCL635 and ABCL575 advanced in clinical development.
AbCellera Biologics Inc. reported Q2 2026 financial and operational results. Total revenue was $4.1 million, compared with $17.1 million in Q2 2025, and the company posted a net loss of $55.4 million, or $(0.18) per share, versus a net loss of $34.7 million, or $(0.12) per share, a year earlier.
The company highlighted pipeline progress, including completed enrollment in the Phase 2 trial of ABCL635 with top-line data expected in August 2026, and completed dosing in the Phase 1 study of ABCL575 with data expected in Q4 2026. ABCL386 and ABCL688 are in IND-enabling activities, and partners led 35 programs with downstream participation, including 12 molecules in the clinic as of June 30, 2026.
AbCellera expanded its T-cell engager collaborations, signing a Jazz Pharmaceuticals agreement with $84 million in total upfront payments and eligibility for up to $792 million per program in option and milestone payments plus tiered royalties, and a Vertex collaboration providing $28 million in upfront payments with further milestone and royalty potential. The company emphasized a strong liquidity position with over $565 million in cash balances and marketable securities and more than $675 million in total available liquidity, including $110 million in available non-dilutive government funding.
AbCellera Biologics Inc. entered into a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera will use its proprietary T-cell engager platform to lead discovery and early development.
Vertex will fund all research and development costs and will have the right to develop and commercialize therapeutic multispecific antibodies arising from the collaboration. AbCellera will receive $28 1 million in total upfront payments and is eligible for additional milestone payments and tiered royalties on net sales, with an option for AbCellera to provide development and clinical manufacturing through Phase 1 by mutual agreement.
AbCellera Biologics Inc. director Lynn Seely received a grant of share options covering 152,207 common shares. The options have an exercise price of $7.85 per share and expire on July 1, 2036. They vest in three equal annual installments beginning July 1, 2027, contingent on continued service.
AbCellera Biologics Inc. director Lynn Seely has filed a Form 3, which is an initial statement of beneficial ownership for insiders. The structured data for this filing shows no reported transactions in AbCellera securities and no listed derivative positions for the reporting person.
AbCellera Biologics Inc. director Sandor Victor received a grant of options covering 152,207 common shares on July 1, 2026. These share options have an exercise price of $7.85 per share and expire on July 1, 2036.
The options vest in three substantially equal annual installments, with the first tranche scheduled to vest on July 1, 2027, subject to his continued service with the company. After this grant, he holds options on 152,207 shares directly.
AbCellera Biologics Inc. has appointed Lynn Seely, M.D., as a new Class III independent director on its Board of Directors. She will serve until the company’s 2029 annual meeting of shareholders and until a successor is elected and qualified or she departs earlier.
The Board determined that Dr. Seely is independent under Nasdaq rules and the company’s corporate governance guidelines. She will receive compensation under AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors, with no related-party transactions or appointment arrangements disclosed.
Dr. Seely is president and CEO of Lyell Immunopharma Inc. and previously led Myovant Sciences Inc. and served as chief medical officer of Medivation Inc., where she oversaw development of the oncology drug Xtandi. A press release with additional background is included as Exhibit 99.1.
AbCellera Biologics Inc. entered a preclinical research collaboration, option and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The collaboration includes $56 million in upfront payments to AbCellera for two initial programs, with a commitment to start a third program within 12 months. AbCellera will receive an additional $28 million upon initiation of the third program and is eligible for up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments, plus tiered royalties on net sales ranging from mid-single digits to low double-digits.
AbCellera Biologics Inc. director Michael R. Hayden received a grant of share options covering 111,701 common shares. The options have an exercise price of $5.27 per share, expire on June 11, 2036, and represent compensation rather than an open-market purchase.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, subject to his continuous service with AbCellera through that date. Following this award, he holds options on a total of 1,011,544 underlying common shares directly.
AbCellera Biologics Inc. director Stephen Quake received a grant of 111,701 share options giving the right to buy an equal number of common shares at an exercise price of $5.27 per share. After this grant, Quake holds share options for a total of 306,633 common shares.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, provided Quake continues to serve the company through that date. This is a compensation-related award rather than an open-market stock trade.